Treatment of men with minimally symptomatic benign prostatic hyperplasia - PRO: The argument in favor

Urology

Volumn 62, Issue 5, 2003, Pages 781-783

  Marks, Leonard S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Urological Sci Research Foundation   (United States)

^c Urological Sci Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; OXIDOREDUCTASE INHIBITOR; PLACEBO;

BLEEDING; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; EDITORIAL; HEART INFARCTION; HIP FRACTURE; HUMAN; MALE; MORBIDITY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATISM; PROSTATITIS; RISK FACTOR; STONE FORMATION; STROKE; SYMPTOM; URINE RETENTION;

EID: 0242412510     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00779-9     Document Type: Editorial

References (16)

1. Young HH: Benign hypertrophy of the prostate, in Young HH (Ed): Young's Practice of Urology. Philadelphia, WB Saunders, 1926, vol I, p 468.
2. Walsh PC: Benign prostatic hyperplasia, in Walsh PC, Retik AB, Vaughan ED Jr, et al (Eds): Campbell's Urology, 6th ed. Philadelphia, WB Saunders, 1992, vol I, p 1024.
3. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
4. Roehrborn C.G., Boyle P., Nickel C., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:2002;434-441.
5. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol. 163:2000;13-20.
6. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol. 161:1999;1174-1179.
7. Kirby R.S., McConnell J.D. Benign Prostatic Hyperplasia. 1995;Health Press, Oxford.
8. Roberts R.O., Jacobsen S.J., Jacobson D.J., et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 163:2000;107-113.
9. Arighi H.M., Metter E.J., Guess H.A. Natural history of benign prostatic hyperplasia and risk of prostatectomy. Urology. 38:(suppl 1):1991;4-8.
10. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism risk factors for acute urinary retention. J Urol. 158:1997;481-487.
11. Jacobsen S.J., Girman C.J., Lieber M.M. Natural history of benign prostatic hyperplasia. Urology. 58:(suppl 6A):2001;5-16.
12. Roehrborn C.G., Boyle P., Gould L., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53:1999;581-589.
13. Roehrborn C.G., McConnell J.D., Lieber M.M., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with benign prostatic hyperplasia. Urology. 53:1999;473-480.
14. Wright E.J., Fang J., Metter E.J., et al. Prostate-specific antigen predicts the long-term risk of prostate enlargement results from the Baltimore Longitudinal Study of Aging. J Urol. 167:2002;2484-2487.
15. Carson C., Rittmaster R.S. Role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 61:(suppl 4A):2003;2-7.
16. Andriole G.L., Guess H.A., Epstein J.I., et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 52:1998;195-201.